Losasso C, Loffreda A, Angrisani M, Contaldi C, Cazzola M, Rossi F
Institute of Pharmacology and Toxicology, Medical School, 2nd University of Naples, Italy.
J Chemother. 1995 Oct;7(5):420-3. doi: 10.1179/joc.1995.7.5.420.
Platelet aggregation is inhibited by high concentrations of most antibiotics. For this reason it is important to evaluate the effects of new antimicrobial agents on platelet aggregation. Lomefloxacin and sparfloxacin are new difluorinated quinolone antimicrobial agents. The aim of this work was to evaluate in vitro the effects of lomefloxacin and sparfloxacin on adenosinediphosphate (ADP) and collagen-induced human platelet aggregation. Our data showed that both antibiotics (lomefloxacin and sparfloxacin) at therapeutic doses did not inhibit in vitro human platelet aggregation. Lomefloxacin, only at the highest tested concentration (1 mg/ml), which is far higher than the clinically achievable one, significantly (P < 0.05) inhibited collagen-induced platelet aggregation. Sparfloxacin also caused inhibition of collagen and ADP-induced human platelet aggregation only at the highest tested concentration (0.01 mg/ml), which is higher than that reached in vivo. These findings suggest that therapeutic doses of lomefloxacin and sparfloxacin do not affect human platelet aggregation.
大多数抗生素在高浓度时会抑制血小板聚集。因此，评估新型抗菌药物对血小板聚集的影响很重要。洛美沙星和司帕沙星是新型二氟喹诺酮类抗菌药物。这项研究的目的是在体外评估洛美沙星和司帕沙星对二磷酸腺苷（ADP）和胶原诱导的人血小板聚集的影响。我们的数据表明，两种抗生素（洛美沙星和司帕沙星）在治疗剂量下均未在体外抑制人血小板聚集。仅洛美沙星在最高测试浓度（1mg/ml）时，该浓度远高于临床可达到的浓度，才显著（P<0.05）抑制胶原诱导的血小板聚集。司帕沙星也仅在最高测试浓度（0.01mg/ml）时才导致对胶原和ADP诱导的人血小板聚集的抑制，该浓度高于体内达到的浓度。这些发现表明，洛美沙星和司帕沙星的治疗剂量不会影响人血小板聚集。
